相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients
Krisstina Gowin et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Improving Survival Trends in Primary Myelofibrosis: An International Study
Francisco Cervantes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
Robyn M. Emanuel et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management
Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Comparison of thalidomide and lenalidomide as therapy for myelofibrosis
Elias Jabbour et al.
BLOOD (2011)
Indications for and current results with allogeneic hematopoietic cell transplantation in patients with myelofibrosis
H. Joachim Deeg et al.
BLOOD (2011)
Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report
Richard T. Silver et al.
BLOOD (2011)
The renaissance of interferon therapy for the treatment of myeloid malignancies
Jean-Jacques Kiladjian et al.
BLOOD (2011)
Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis
S. Lissandre et al.
BONE MARROW TRANSPLANTATION (2011)
Therapeutic approaches in myelofibrosis
Giovanni Barosi et al.
EXPERT OPINION ON PHARMACOTHERAPY (2011)
DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
Naseema Gangat et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Interferon Alfa in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms
Hans Carl Hasselbalch et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Animesh Pardanani et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
Tiziano Barbui et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A phase-2 trial of low-dose pomalidomide in myelofibrosis
K. H. Begna et al.
LEUKEMIA (2011)
Transplantation for myelofibrosis: Time for a randomized trial
Ruben A. Mesa
LEUKEMIA RESEARCH (2011)
What are RBC-transfusion-dependence and -independence?
R. P. Gale et al.
LEUKEMIA RESEARCH (2011)
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Francesco Passamonti et al.
BLOOD (2010)
Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903
Ruben A. Mesa et al.
BLOOD (2010)
Alpha interferon in the treatment of symptomatic myelofibrosis with myeloid metaplasia
L. Parmeggiani et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria
Martha Wadleigh et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2010)
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Francisco Cervantes et al.
BLOOD (2009)
PEG-IFN-α-2a therapy in patients with myelofibrosis
Jean-Christophe Ianotto et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
Alfonso Quintas-Cardama et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
Jean-Jacques Kiladjian et al.
BLOOD (2008)
PEG-IFN-α-2b therapy in BCR-ABL-negative myeloproliferative disorders -: Final result of a phase 2 study
Elias Jabbour et al.
CANCER (2007)
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)
Ayalew Tefferi et al.
BLOOD (2006)
Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: A phase II trial
M Marchetti et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
分享论文
